|
Andrew is an investor and entrepreneur who recently joined the InCube team to focus on all aspects of company creation, alongside Mir Imran. Andrew is also an active member of InCube Ventures, where he serves as a Partner.
Prior to joining InCube, Andrew was an active investor with The Angels’ Forum and a Partner in the Halo Funds, where he completed a Kauffman Fellowship and led investments in a portfolio of life science firms. These investments include Intrapace (obesity), Penumbra (ischemic stroke), Sonoma Orthopedic Products, SwitchGear Genomics & Spinal Modulation (pain management).
Earlier in his career, Andrew served as Senior Vice President of sales and marketing for QIAGEN Operon, where he grew revenues of synthetic DNA products from $13 to $40M in two years, and played a key role in selling the business for nine figures. In his earlier career, Andrew held several roles in research operations at Genentech, Inc. and co-founded a gene design business in agricultural biotechnology. He has also developed strategies for healthcare firms as a consultant.
Andrew holds a Masters of Business Administration from Harvard University and a Bachelor’s with high honors from the University of California at Berkeley.
|
